Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, addresses the increased mortality that is seen in patients with sickle cell disease (SCD) during the transition from pediatric to adult care. He mentions the importance of educating hematologists about the most effective treatment strategies for these patients so they can access potentially curative allogeneic stem cell transplantation (alloSCT) and gene therapies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть